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Recovery of Mycobacterium haemophilum skin infection 
in an HIV-I-infected patient after the start of antiretroviral 
triple therapy 
Clin Microbiol Infect 1997; 3: 584-585 
A 30-year-old Caucasian HIV-1-infected woman with 
a history of Pneumocystis carinii pneumonia presented 
with multiple painful cutaneous nodules on the extre- 
mities. Her CD4’ T-cell count was 50/mm3. She had 
recently returned from the island of St Maarten, where 
she had lived for 4 years. Her medication included co- 
trimoxazole 480 mg once daily as PCP prophylaxis, and 
zidovudine 200 mg three times daily with zalcitabine 
0.75 mg three times daily as antiretroviral therapy. 
Physical examination revealed tender, erythematous 
nodular lesions on the extremities, especially overlying 
the knee, the first metatarsal and elbows. A few ulcera- 
tive lesions discharged purulent material. Microscopic 
examination of biopsy specimens revealed a purulent 
inflammatory reaction with many acid-fast bacilli. A 
Mycobacterium marinum skin infection was suspected and 
the skin lesions resolved subsequent to treatment with 
doxycycline 200 mg once daily for two months. 
Two weeks after discontinuation of doxycycline, 
however, the skin lesions relapsed and rapidly pro- 
gressed despite retreatment with doxycycline. A second 
biopsy was performed and Mycobacterium haemophilum 
was identified using a nested P C R  of 16s rRNA gene 
fragments followed by direct sequence determination 
[l]. Cultures of the skin biopsy on Middlebrook 7H11 
medium supplemented with 60 pmol hemin revealed 
M.  haemophilum after 3 weeks of incubation at 30°C. 
Antibiotic susceptibility tests were not performed. The 
skin lesions failed to respond to treatment with cipro- 
floxacin 750 mg twice daily, rifampin 600 mg once 
daily and clarithromycin 500 mg twice daily for 8 
weeks, and progressed further despite a change of 
therapy to minocycline 100 mg once daily, rifabutin 
300 mg once daily and ethambutol 15 mg per kg once 
dailv. New mutilating skin lesions develoDed in the 
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patient’s condition improved remarkably and the skin 
lesion slowly healed with formation of scars. After 
2 months of treatment, all ulcerating skin lesions had 
disappeared except for a residual lesion in the knee. 
A reduction in the number of plasma HIV RNA 
copies from 12 000 copies per mL to values below the 
detection limit (1000 copies per mL, NASBA-QT; 
S h o r t  C o m m u n i c a t i o n s  a n d  L e t t e r s  t o  t h e  E d i t o r s  585 
ORGANON, TEKNIKA, Boxtel, The Netherlands) 
and an increase of the cell-mediated immunity as 
reflected by an amelioration of T-cell stimulation tests 
with CD3 monoclonal antibodies (3-400/0 in com- 
parison with the response in healthy controls) was 
observed. The CD4+ T-cell count had been modestly 
increased from 50/mm3 to 70/mm3. 
M.  haemophilum, the ‘blood-loving mycobacterium’, 
was first described in 1978 as a cause of subcutaneous 
infection in a patient with Hodgkin’s disease [2]. M. 
haemophilum causes cutaneous lesions (similar to the 
related M.  marinum and M.  ulcerans), arthritis, and 
pulmonary infections in immunocompromised patients 
[3]. These cutaneous lesions are most often found 
on the extremities, especially overlying the joints, 
and are not sporotrichoid in appearance. Of  64 cases of 
M.  haemophilum infections reviewed recently, 53 have 
been reported in immunocompromised adults, nine 
have been reported in children, primarily as localized 
lymphadenitis in the cervical region or perihilar 
lymphadenitis, and two have been reported in adults 
whose risk factors were not known [3]. Culture-proven 
M.  haemophilum infections in immunocompetent adults 
have not been reported. The most frequent underlying 
diseases associated with M. haemophilum infections were 
AIDS, renal transplant recipients, bone marrow trans- 
plant recipients, lymphoma, and rheumatoid arthritis. 
The natural habitat of M .  haernophilum is unknown 
and attempts to recover it from environmental samples 
have been unsuccessful. The geographic distribution 
of reported M .  haemophilum cases suggests that the 
bacterium is ubiquitous but the means of acquisition of 
the organism remain unknown, even when clustering 
of cases occur [4,5]. 
There are no standardized methods for anti- 
microbial susceptibility testing of M.  haemophilum. A 
variety of agar methods and a broth microdilution 
method have been described in the case reports. One 
study reports on a larger number of isolates (n=17) 
which were tested using a modification of a inicro- 
dilution broth method [6].  Ethambutol, tetracycline 
and trimethoprim-sulfamethoxazol were inactive against 
M.  haemophilum, whereas isoniazid was weakly active 
and ciprofloxacin, ofloxacin and sparfloxacin showed 
moderate activity. The most active antimicrobial agents 
were clarithroniycin and rifabutin. Additionally, com- 
bined rifabutin and clarithromycin provided effective 
treatment for experimentally induced disseminated M .  
haemophilum infection in irnniunocompromised mice 
Twenty-nine of the approximately 60 cases of M .  
haemophilum infection reported worldwide were diag- 
nosed in HIV-I-infected individuals who appeared 
to have a strong immunodeficiency (CD4+ count 
~71. 
<50/mm3). In only six of these 29 patients did skin 
lesions resolve after the initiation of antimycobacterial 
therapy. The contribution of antibiotics to the heal- 
ing of M .  haemophilum lesions is difficult to evaluate. 
Recovery from M. haemophilum infections niay depend 
mostly on an improvement of the immunologic state or 
surgical drainage [8]. Our observation in this patient 
suggests that, in addition to antimycobacterial anti- 
biotic treatment, improvement of the cell-mediated 
immunity induced by antiretroviral triple therapy con- 
tributes considerably to the recovery from a persistent 
M. haemophilum skin infection. 
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